MktsMarkets

Compass Therapeutics, Inc.
NASDAQ: CMPXKey statistics
CMPX News
Stories mentioning CMPX from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 13,390 | 13,674 | 12,826 | 16,415 | 13,054 | 13,034 | 8,612 | 11,174 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 20,299 | 17,990 | 15,817 | 21,066 | 17,966 | 16,571 | 12,239 | 15,895 |
| Operating Income (Loss) | (20,299) | (17,990) | (15,817) | (21,066) | (17,966) | (16,571) | (12,239) | (15,045) |
| Interest Income | 1,200 | 1,300 | 1,500 | 1,800 | 2,000 | |||
| Interest Expense | ||||||||
| Other Expense | 1,982 | 2,274 | 1,558 | 1,185 | 1,333 | 1,540 | 1,758 | 1,969 |
| Pretax Income | (16,633) | (13,076) | ||||||
| Tax Provision | 0.00 | 0.00 | ||||||
| Net Income (Loss) | (18,317) | (15,716) | (14,259) | (19,881) | (16,633) | (15,031) | (10,481) | (13,076) |
| Earnings Per Share (Basic) | (0.10) | (0.10) | (0.08) | (0.14) | (0.12) | (0.11) | (0.08) | (0.10) |
| Earnings Per Share (Diluted) | ||||||||
| Weighted Average Shares Outstanding (Basic) | 186,400 | 157,695 | 168,782 | 138,282 | 138,236 | 137,384 | 137,589 | 137,589 |
| Weighted Average Shares Outstanding (Diluted) | 138,200 | 137,600 | ||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About CMPX
Compass Therapeutics, Inc. (NASDAQ: CMPX) is a stock listed on the Nasdaq Stock Market under the ticker symbol CMPX. It last traded at $0.8400 (Nov 9, 2026, 4:00 PM ET), up 10.3% on the day. That gives Compass Therapeutics a market capitalisation of $150.7M.
Over the past 52 weeks CMPX has traded between $0.6700 and $6.88.
For the quarter ended Mar 31, 2026 it reported a net loss of $18.3M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$18.3M |
| Dec 31, 2025 | — | -$15.7M |
| Sep 30, 2025 | — | -$14.3M |
| Jun 30, 2025 | — | -$19.9M |
From Compass Therapeutics’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…